Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,828 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 35,000 · Balance 122,828 F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates.
F2: Includes shares of restricted common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkpoint Therapeutics, Inc.
Report date May 30, 2025 · Filed May 30, 2025
Section 16 reporting ended · disclosed 2025-05-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-30 transaction · row 1
1 source rowRow 1 · 2025-05-30 · Other · Disposed 3,759,929 · Balance 0 F1: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:11 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073460 · tm2617536-3_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,828 F1 · shares: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 20:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058916 · tm2517867-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,828 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the Company's Board of Directors on such dates. Read SEC document |
| May 30, 2025 Filed May 30, 2025 11:18 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | OtherCOMMON STOCK | 3,759,929 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-054690 · tm2516581-5_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of in connection with an offer made pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025 and as amended on April 14, 2025 (the "Merger Agreement"), in exchange for $4.10 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share. Each CVR represents the right to receive a payment ranging from $0.20 to $0.70 pursuant to certain milestone payments as defined in the Merger Agreement relating to the regulatory approval for cosibelimab in the European Union. The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application or equivalent application for cosibelimab receives a positive validation outcome by the European Medicines Agency. Read SEC document |
| April 02, 2025 Filed Apr 3, 2025 19:27 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 15,090 | $4.04 | $60,963.60 |
DisclosureSEC source: 0001104659-25-031813 · tm2511508-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,759,929 F1 · kind: In connection with the vesting of restricted shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 21:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 10,331 | $3.15 | $32,542.65 |
DisclosureSEC source: 0001104659-25-011656 · tm256253-1_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,775,019 F1 · kind: In connection with the vesting of restricted shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F4 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.14 to $3.16. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 9,233 | $3.41 | $31,484.53 |
DisclosureSEC source: 0001104659-25-011656 · tm256253-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,785,350 F1 · kind: In connection with the vesting of restricted shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.40 to $3.41. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008258 · tm255136-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,794,583 F1 · shares: The shares of restricted stock vest as follows: one-third on January 30, 2026, one-third on January 30, 2027, and January 30, 2028. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| December 20, 2024 Filed Dec 20, 2024 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCOMMON STOCK | 900,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-130963 · tm2431781-2_4seq1.xml · nonDerivative · entry 3 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,294,583 F5 · kind: On December 20, 2024, 900,000 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 220,230 | $3.38 | $744,377.40 |
DisclosureSEC source: 0001104659-24-130963 · tm2431781-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194,583 F1 · kind: In connection with the vesting of 2,111,033 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F4 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.33 to $3.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 602,167 | $3.87 | $2,330,386.29 |
DisclosureSEC source: 0001104659-24-130963 · tm2431781-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,414,813 F1 · kind: In connection with the vesting of 2,111,033 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.66 to $4.27. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:32 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 2,077,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-129525 · tm2431396-5_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,016,980 F1 · shares: Represents previously-granted performance-based award that became vested upon achievement of a corporate milestone on December 13, 2024. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:01 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCOMMON STOCK | 37,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-076442 · tm2418524-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,939,280 F4 · kind: On June 26, 2024, 37,890 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:01 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 24,610 | $2.05 | $50,450.50 |
DisclosureSEC source: 0001104659-24-076442 · tm2418524-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,977,170 F1 · kind: In connection with the vesting of 62,500 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $2.05 to $2.0504. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 20:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071284 · tm2416958-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,828 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the board on such dates. Read SEC document |
| May 24, 2024 Filed May 24, 2024 21:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 1,660,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-065214 · tm2415549-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,001,780 F1 · shares: The shares of restricted stock vest as follows: one-third on January 31, 2025, one-third on January 31, 2026 and one-third on January 31, 2027. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCOMMON STOCK | 9,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-030149 · tm247659-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,780 F4 · kind: On February 28, 2024, 9,056 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 5,894 | $2.06 | $12,141.64 |
DisclosureSEC source: 0001104659-24-030149 · tm247659-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,836 F1 · kind: In connection with the vesting of 14,950 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $2.06 to $2.075. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 20:10 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCOMMON STOCK | 12,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010265 · tm245141-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,730 F4 · kind: On February 1, 2024, 12,950 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 20:10 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 11,900 | $2.01 | $23,919.00 |
DisclosureSEC source: 0001104659-24-010265 · tm245141-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,680 F1 · kind: In connection with the vesting of 24,850 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $2.00 to $2.0104. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| August 16, 2023 Filed Feb 2, 2024 20:05 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCommon Stock | 12,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010262 · tm245141-3_5seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,580 F3 · kind: On August 16, 2023, 12,510 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 12:16 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072607 · tm2319007-3_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,828 F1 · shares: The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Oliviero's continued service on the board on such dates. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041761 · tm2311770-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,090 F1 · shares: The shares of restricted stock vest as follows: one-fourth on March 31, 2024, one-fourth on March 31, 2025, one-fourth on March 31, 2026 and one-fourth on March 31, 2027. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 5,483 | $5.00 | $27,415.00 |
DisclosureSEC source: 0001104659-23-028603 · tm238194-2_4seq1.xml · nonDerivative · entry 3 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,090 F5 · kind: In connection with the vesting of 15,000 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F6 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $5.00 to $5.03. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 27, 2023 Filed Mar 3, 2023 20:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-028603 · tm238194-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,573 F4 · kind: Represents previously-granted performance-based award that became vested upon achievement of a corporate milestone on February 27, 2023. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 27, 2023 Filed Mar 3, 2023 20:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 5,548 | $4.65 | $25,798.20 |
DisclosureSEC source: 0001104659-23-028603 · tm238194-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,573 F1 · kind: In connection with the vesting of 14,950 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $4.65 to $4.6833. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 24, 2023 Filed Feb 2, 2024 20:05 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010262 · tm245141-3_5seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,580 F1 · kind: On February 24, 2023, 42,000 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F2 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 20:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 10,261 | $4.77 | $48,944.97 |
DisclosureSEC source: 0001104659-23-010771 · tm235395-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,121 F1 · kind: In connection with the vesting of 23,500 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $4.76 to $4.82. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 20:05 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 3,817 | $6.75 | $25,760.93 |
DisclosureSEC source: 0001104659-23-003529 · tm233206-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,382 F1 · kind: In connection with the vesting of 13,475 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $6.60 to $6.90. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| September 26, 2022 Filed Jan 12, 2023 20:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GiftCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003528 · tm233206-3_5.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,199 F1 · kind: On September 26, 2022, shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust. F2 · shares: Checkpoint Therapeutics, Inc. effected a reverse stock split on December 6, 2022. The reported number gives effect to this reverse stock split. F3 · balance_after: Includes shares of restricted common stock, which vest over various time periods. Read SEC document |
| June 23, 2022 Filed Jul 1, 2022 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 15,000 | $1.11 | $16,650.00 |
DisclosureSEC source: 0001104659-22-076976 · tm2220291-1_4seq1.xml · nonDerivative · entry 4 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,562,003 F5 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.11 to $1.13. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 22, 2022 Filed Jul 1, 2022 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 12,000 | $1.09 | $13,080.00 |
DisclosureSEC source: 0001104659-22-076976 · tm2220291-1_4seq1.xml · nonDerivative · entry 3 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577,003 F4 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.09 to $1.10. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 21, 2022 Filed Jul 1, 2022 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 21,000 | $1.09 | $22,890.00 |
DisclosureSEC source: 0001104659-22-076976 · tm2220291-1_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,589,003 F3 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.06 to $1.12. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 17, 2022 Filed Jul 1, 2022 21:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 228,000 | $1.09 | $248,520.00 |
DisclosureSEC source: 0001104659-22-076976 · tm2220291-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,610,003 F1 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.06 to $1.12. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| April 13, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 21,258 | $1.51 | $32,099.58 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 8 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,838,003 F5 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.51 to $1.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| April 05, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 14,030 | $1.77 | $24,833.10 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 7 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859,261 F4 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.75 to $1.78. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| April 04, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 86,353 | $1.79 | $154,571.87 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 6 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,873,291 F3 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $1.77 to $1.81. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:47 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001104659-22-042817 · tm2211420-4_4seq1.xml · derivative · entry 1 Oliviero James F III · CIK 0001434718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The options will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. Read SEC document |
| February 24, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Tax withholdingCOMMON STOCK | 117,657 | $1.85 | $217,665.45 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 5 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,959,644 F1 · shares: Consists of shares withheld by the Issuer with respect to the reporting person's tax withholding obligations upon the vesting and delivery of shares of common stock underlying restricted stock units previously granted by the issuer. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 19:00 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 455,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010997 · tm225237-1_4.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,608,210 F1 · shares: The shares of restricted stock vest as follows: one-fourth on January 31, 2023, one-fourth on January 31, 2024, one-fourth on January 31, 2025 and one-fourth on January 31, 2026 F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 30, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Tax withholdingCOMMON STOCK | 31,972 | $2.46 | $78,651.12 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 4 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077,301 F1 · shares: Consists of shares withheld by the Issuer with respect to the reporting person's tax withholding obligations upon the vesting and delivery of shares of common stock underlying restricted stock units previously granted by the issuer. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 24, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Tax withholdingCOMMON STOCK | 143,136 | $2.19 | $313,467.84 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 3 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,109,273 F1 · shares: Consists of shares withheld by the Issuer with respect to the reporting person's tax withholding obligations upon the vesting and delivery of shares of common stock underlying restricted stock units previously granted by the issuer. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 06, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Tax withholdingCOMMON STOCK | 53,024 | $2.77 | $146,876.48 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,252,409 F1 · shares: Consists of shares withheld by the Issuer with respect to the reporting person's tax withholding obligations upon the vesting and delivery of shares of common stock underlying restricted stock units previously granted by the issuer. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 01, 2022 Filed Apr 22, 2022 20:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | Tax withholdingCOMMON STOCK | 302,777 | $3.11 | $941,636.47 |
DisclosureSEC source: 0001104659-22-049156 · tm2213359-1_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,305,433 F1 · shares: Consists of shares withheld by the Issuer with respect to the reporting person's tax withholding obligations upon the vesting and delivery of shares of common stock underlying restricted stock units previously granted by the issuer. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| February 05, 2021 Filed Feb 5, 2021 20:16 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 48,790 | $3.42 | $166,744.70 |
DisclosureSEC source: 0001104659-21-013180 · tm215541-2_4seq1.xml · nonDerivative · entry 2 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,153,210 F1 · kind: In connection with the vesting of 243,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted by the Company in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.35 to $3.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 20:16 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | SaleCOMMON STOCK | 70,000 | $3.51 | $245,525.00 |
DisclosureSEC source: 0001104659-21-013180 · tm215541-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202,000 F1 · kind: In connection with the vesting of 243,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted by the Company in accordance with the Company's corporate policies regarding the vesting of restricted stock. F2 · price: Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.50 to $3.525. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F4 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 16:31 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 539,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-002489 · tm212167-2_4seq1.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272,000 F1 · shares: The shares of restricted stock vest as follows: one-fourth on January 6, 2022, one-fourth on January 6, 2023, one-fourth on January 6, 2024 and one-fourth on January 6, 2025. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 19:01 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 598,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-024924 · tm2010923d1_form4.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,733,000 F1 · shares: The shares of restricted stock vest as follows: one-half on February 24, 2022, one-fourth on February 24, 2023, and one-fourth on February 24, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 16:30 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 485,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-002890 · tv511635_form4.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · Director · CEO, President and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,135,000 F1 · shares: The shares of restricted stock vest as follows: one-half on January 24, 2021, one-fourth on January 24, 2022 and one-fourth on January 24, 2023. F2 · balance_after: Includes 1,000,000 shares of restricted stock that were granted on October 13, 2015, 325,000 shares of restricted stock that were granted on December 15, 2016, and 325,000 shares of restricted stock that were granted on January 30, 2018, all previously reported. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 18:41 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 325,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-005239 · tv484690_form4.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650,000 F1 · shares: The shares of restricted stock vest as follows: one-half on January 30, 2020, one-fourth on January 30, 2021 and one-fourth on January 30, 2022. F2 · balance_after: Includes (a) 1,000,000 shares of restricted stock that were granted on October 13, 2015, as previously reported, and are scheduled to vest as follows: (i) 444,444 shares on October 13, 2019; (ii) 222,222 shares on the later of April 1, 2019 or the Company's achievement of market capitalization goals; and (iii) 333,334 shares on the Company's achievement of goals relating to corporate development transactions and/or FDA approval; (b) 325,000 shares of restricted stock that were granted on December 15, 2016, as previously reported, and are scheduled to vest as follows: (i) 243,750 shares on December 15, 2019; and (ii) 81,250 shares on December 15, 2020; and (c) the 325,000 shares of restricted stock that were granted on January 30, 2018, as reported herein. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 18:05 UTC | Checkpoint Therapeutics, Inc. CKPT · Entity 78931 | GrantCOMMON STOCK (RESTRICTED) | 325,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-16-140339 · v455312_4.xml · nonDerivative · entry 1 Oliviero James F III · CIK 0001434718 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325,000 F1 · shares: The shares of restricted stock vest as follows: One-half on December 15, 2018, one-fourth on December 15, 2019 and one-fourth on December 15, 2020. F2 · balance_after: Represents shares of restricted stock which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.